If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
SPECIAL DIGITAL SUPPLEMENT
SPONSORED CONTENT BY GUERBET
THE MAGAZINE OF DISTINCTION IN RADIOLOGY
WHY TWO IMAGING
CENTERS CHANGED THEIR
CONTRAST MEDIUM
Switching
to Dotarem®
Why Two Imaging Centers Changed
Their Contrast Medium
IMPORTANT SAFETY INFORMATION1
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of
GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
· The risk for NSF appears highest among patients with:
o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or
o Acute kidney injury.
· Screen patients f
SPECIAL DIGITAL SUPPLEMENT SPONSORED CONTENT BY G
Switching to Dotarem® Why Two Imaging Centers Cha
Interview with Ryan Garland, MHA, BS, RT (R), Sys
Interview with Mark L. Winkler, MD, President of
IMPORTANT SAFETY INFORMATION CONT.1 Indication
MRI Interconnected Solutions CONTRAST AGENT I